Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients

BACKGROUND: Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wimmer, Kerstin, Sachet, Monika, Ramos, Cristiano, Frantal, Sophie, Birnleitner, Hanna, Brostjan, Christine, Exner, Ruth, Filipits, Martin, Bago-Horvath, Zsuzsanna, Rudas, Margaretha, Bartsch, Rupert, Gnant, Michael, Singer, Christian F., Balic, Marija, Egle, Daniel, Oehler, Rudolf, Fitzal, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644559/
https://www.ncbi.nlm.nih.gov/pubmed/37957750
http://dx.doi.org/10.1186/s13046-023-02876-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644559/
https://www.ncbi.nlm.nih.gov/pubmed/37957750
http://dx.doi.org/10.1186/s13046-023-02876-x

Ejemplares similares